Pure Global AI
NCT05891821Not yet recruiting

Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)

Immune Oncology Research InstitutePhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Lymphoma
Drug/Device/Intervention
Balstilimab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Immune Oncology Research Institute
Location
Yerevan, Armenia
Timeline & enrollment
Phase
Phase 2
Start date
Jun 01, 2023
End date
Jun 01, 2029
Enrollment
20 participants
Primary outcome

Objective Response Rate (ORR)

Summary

The goal of this study is to see if the drug balstilimab is safe and effective in
 participants with relapsed/refractory lymphomas.
 
 Participants will receive balstilimab every 3 weeks and their outcomes will be assessed
 periodically.

ICD-10 classifications
Hodgkin lymphomaFollicular lymphomaNon-Hodgkin lymphoma, unspecifiedFollicular lymphoma, unspecifiedHodgkin lymphoma, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05891821
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05891821 through Pure Global AI's free database. This Phase 2 trial is sponsored by Immune Oncology Research Institute and is currently Not yet recruiting. The study focuses on Lymphoma. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.